TherOx specializes in advanced medical technology aimed at improving outcomes for patients suffering from severe heart attacks. The company's flagship product, the TherOx DownStream System, is designed to deliver SuperSaturated Oxygen (SSO2) Therapy to ischemic regions of the heart. This therapy is specifically targeted at the left anterior descending coronary artery immediately following revascularization procedures like percutaneous coronary intervention (PCI) with stenting. The primary goal is to minimize damage to heart tissue, thereby reducing mortality and hospitalization rates associated with heart failure.

TherOx operates in the medical device market, primarily serving healthcare providers and physicians who specialize in cardiology and emergency care. The business model is centered around the sale of its proprietary technology and related services, generating revenue through direct sales and partnerships with healthcare institutions.

The company has received regulatory approvals, including CE Mark and FDA approval, which validate the efficacy and safety of its SSO2 Therapy. These approvals enable TherOx to market its products in both the United States and Europe, expanding its reach and potential market share.

TherOx's innovative approach and proven clinical outcomes position it as a leader in the cardiac care industry, offering a unique solution that addresses a critical need in emergency heart attack treatment.

Keywords: SuperSaturated Oxygen, ischemic heart tissue, PCI, stenting, hyperbaric infusate, cardiology, heart attack, revascularization, FDA approval, CE Mark.